Trial Profile

A Study to Evaluate the Efficacy and Safety of Genormab Injection in Chinese Patients With Recurrent or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Geptanolimab (Primary)
Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms GB226
Sponsors Genor Biopharma

Most Recent Events

24 Aug 2023 Status changed from active, no longer recruiting to discontinued, according to Results published in the Cancer Immunology Immunotherapy.
24 Aug 2023 Results published in the Cancer Immunology Immunotherapy
02 Mar 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com